Table 1.
Type of criteria (clinical, laboratory, and management) in maternal near miss cases
| MNM criteria | MNM (SSA), n (%) | MNM (WHO), n (%) | MNM (combined), n (%) | Maternal death, n (%) |
|---|---|---|---|---|
| n=148 | n=69 | n=148 | n=12 | |
| Clinical criteria | 138 (93) | 35 (51) | 138 (93) | 7 (58) |
| Failure to form clots | 35 (24) | 35 (51) | 35 (24) | 2 (17) |
| Stroke | 0 | 0 | 0 | 0 |
| Eclampsia | 60 (41) | NA | 60 (41) | 3 (25) |
| Ruptured uterus | 1 (1) | NA | 1 (1) | 0 |
| Sepsis or severe systemic infection | 0 | NA | 0 | 1 (8) |
| Pulmonary edema | 3 (2) | NA | 3 (2) | 1 (8) |
| Severe preeclampsia with ICU admission | 39 (26) | NA | 39 (26) | 0 |
| Laboratory criteria | 36 (24) | 41 (59) | 41 (28) | 4 (33) |
| Oxygen saturation<90% for >60 min | 17 (11) | 17 (25) | 17 (11) | 2 (16) |
| PaO2/FiO2<200 mm Hg | NA | 5 (7) | 5 (3) | 0 |
| Creatinine level≥300 μmol/L or ≥3.5 mg/dL | 6 (4) | 6 (9) | 6 (4) | 1 (8) |
| Bilirubin level>100 μmol/L or >6.0 mg/dL | NA | 0 | 0 | 1 (8) |
| Acute thrombocytopenia (<50,000 platelets/mL) | 13 (9) | 13 (19) | 13 (9) | 0 |
| Management-based criteria | 14 (9) | 3 (4) | 14 (9) | 4 (33) |
| Use of continuous vasoactive drugs | NA | 0 | 0 | 1 (8) |
| Hysterectomy following infection or hemorrhage | 0 | 0 | 0 | 0 |
| Transfusion of ≥2 (SSA) or ≥5 (WHO) units of blood or red cells | 11 (7) | 0 | 11 (7) | 2 (17) |
| Intubation and ventilation not related to anesthesia | 3 (2) | 3 (4) | 3 (2) | 0 |
| Dialysis for acute renal failure | NA | 0 | 0 | 1 (8) |
| Laparotomy other than cesarean delivery | 0 | NA | 0 | 0 |
ICU, intensive care unit; MNM, maternal near miss; NA, not applicable; SSA, sub-Saharan African; WHO, World Health Organization.
Drechsel. Maternal near-miss and hypertensive disorders of pregnancy. Am J Obstet Gynecol Glob Rep 2022.